View
598
Download
2
Embed Size (px)
Citation preview
www.biocat.cat
BIOREGION OF CATALONIA
CATALONIA
WITH A LONG INDUSTRIAL TRADITION, CATALONIA HASA DENSE AND INNOVATIVE INDUSTRIAL COMMUNITY• 6% OF SPANISH TERRITORY• 16% OF POPULATION (7.5M INHABITANTS)• 20% OF GDP• 47% OF PHARMACEUTICAL INDUSTRY• 19.4% OF BIOTECHNOLOGICAL INDUSTRY• 23% OF INVESTMENT IN R&D
BARCELONA LEADS THE TOP 10 MAJOR EUROPEAN CITIES OF THE FUTURE 2016/2017
CATALONIA IS THE FOURTH REGION IN ALL OF EUROPE IN TERMS OF FOREIGN INVESTMENT ATTRACTION IN 2015Sources: Farmaindustria, Asebio, Financial Times' FDI Markets
BARCELONA
THE BIOREGION OF CATALONIAA COMPETITIVE AND INNOVATIVE LIFE SCIENCES AND HEALTHCARE ECOSYSTEMCatalonia is the most dynamic bioregion in Spain and one of the most active in Europe. With a population of more than 7.5 millions and territory comparable to Finland, Belgium, the Netherlands and Israel, the BioRegion of Catalonia brings together 734 companies and 89 research organizations, including 41 research centers, 15 university hospitals, 11 universities offering life sciences studies, 13 sciences and technology parks with activity in the life sciences and large research facilities like the Alba-Cells Synchroton and the Barcelona Supercomputing Center (BSC). Barcelona and its metropolitan area are home to 90% of the Catalan life sciences industry.
BIOCAT BUILDING NOW WHAT THE ECOSYSTEM NEEDS NEXTBiocat has been a strategic player and catalyst in building the Catalan healthcare and life sciences ecosystem.Created in 2006 by the Government of Catalonia and the Barcelona City Council, Biocat is a foundation that boosts public and private stakeholders in the BioRegion (including companies, groups and research organizations, university hospitals, science parks and other support bodies to innovation) in order to transform knowledge and technology into economic growth and social impact.
SINCE 2000, CATALONIA HAS DEVELOPED ITS OWN SUCCESSFUL RESEARCH ECOSYSTEM
2000
KEY SUCCESS FACTORS:• Sustained funding from Catalan Government • Research centers autonomy• Independent evaluation• Funding based on results• High performance in attracting EU funds• Open talent recruitment program (ICREA)
2016
Source: Biocat Directory (September 2015)
734
89COMPANIES
RESEARCHORGANIZATIONS
THE BIOREGION OF CATALONIA, A GROWING AND INNOVATIVE ECOSYSTEM
BIOTECH
PHARMA
MEDTECH (R&D)
SUPPLIER & ENGINEERING
PROFESSIONAL SERVICES
INVESTMENT ENTITIES
RESEARCH CENTERS
UNIVERSITY HOSPITALS
UNIVERSITIES
SCIENCE & TECHNOLOGY PARKS
TECHNOLOGY CENTERS
LARGE FACILITIES
221
4694
208
13926
41
15
11
137
2
(OUT OF 101 HOSPITALS)
(OFFERING LIFE SCIENCES STUDIES)
EMPLOYMENT AND RESOURCES
Sources: Biocat Directory (Dec. 2014), Catalan Union of Hospitals, Government of Catalonia and SAVI
COMPANIES RESEARCH CENTERS HOSPITALS
+5,000RESEARCHERS
8,700WORKERS
+89,000 WORKERS
5,499RESEARCHERS (EMPLOYED BY THE UNIVERSITY HOSPITALS
AND RESEARCH INSTITUTES)
(195 ESTABLISHMENTS)42,133
BIOTECH14,278
PHARMA9,989
OTHERS6,622
MEDTECH 11,244
WORKERS
COMPANIES HAD REVENUES OF 14,369 M€ AND CONTRIBUTED
WITH 7% TO THE GDPIN CATALONIA
IN 10 YEARS, WORKERS IN R&D HAVE INCREASED 50% AND RESEARCHERS 60%
R&D SPENDING IN CATALONIA REPRESENTS 1.5% OF GDP (2,938 M€)23% OF SPANISH INVESTMENT IN R&D
Source: Farmaindustria, INE (2014)
355 M€PHARMA
INDUSTRY
147 M€ BIOTECH
COMPANIES
666 M€ UNIVERSITIES
AN INTERNATIONAL COMPETITIVE R&D SYSTEM
Source: Government of Catalonia TOTAL AMOUNT OF UNIVERSITIES WORLDWIDE (APROX.): 30,000
ICIQ1ST WORLD INSTITUTION
IN CHEMISTRYMax Plank Institute (2014)
ICFO 1ST WORLD INSTITUTION
IN PHYSICS Max Plank Institute (2013)
11 UNIVERSITY AMONG
THE 49 TOPUNIVERSITIES
IN THE WORLD INSCIENTIFIC
PRODUCTION(UB)
URAP (2015-2016)
33 UNIVERSITIES
AMONGTHE 50 BEST
UNDER50 YEARS
(URV, UAB, UPF)
QS TOP-50 UNIVERSITIESUNDER 50 YEARS (2014)
19TH BEST STUDENTCITY OF
THE WORLD
BARCELONA
QS BEST STUDENTS CITIES 2015
2
2 UNIVERSITIES AMONG THE 200
BEST INTHE WORLD
(UB, UAB)
TIMES HIGHER EDUCATION (2015)
CRG9TH IN THE TOP 100 BEST BIOMEDICAL CENTERS
IN THE WORLDScimago Report (SIR 2013)
33.4
32.8
22.2
18.2
6.7
ARTICLES PER MILLION INHABITANTS(2008-2012)
Source: Government of Catalonia
WITHOUT CATALONIA
In terms of publications inScience & Nature, Catalonia
doubles in numbers countries such as Germany or France
RESEARCHERS WORKING IN CATALONIA PUBLISH AT LEVELS COMPARABLE TO THOSE OF THE LEADING EUROPEAN COUNTRIES
CATALONIA PRODUCES 3.15% OF ALL SCIENTIFIC PRODUCTION IN EUROPE AND 0.99% IN THE WORLD, AND 29% OF PUBLICATIONS IN SPAIN
Source: Scopus / Observatori de la Recerca (OR-IEC), Institut d’Estudis Catalans
THE NUMBER OF LIFE SCIENCESAND HEALTHCARE PUBLICATIONS ROSE 168% FROM 2000 TO 2015
Publications(life sciences)
% EU28 % world
20092004 20112006 20102005 20082003200220012000 20122007 2013 2014 2015
4%
5%
2%
3%
1%
0%
10K
12,5K
5K
7,5K
2,5K
0K
THE MORE CHALLENGING AND COMPETITIVE A CALL IS,THE BETTER CATALONIA PERFORMSEUROPEAN RESEARCH COUNCIL (ERC) CALLS ARE THE MOST RESTRICTIVE AMONG EU'S CALLS (LESS THAN 10% APPLICATIONS ARE AWARDED)
With 27 grants per million inhabitants, Catalonia ranks 4th
in the European Research Area and 2nd in the European Union
COUNTRY ERC GRANTS PER MILLION INHABITANTS (2007-2015)
51.946.3
34.527.3
23
21.118.3
17.9
16.217.3
14.811.911.9
11.010.7
10
8.39.3
5.85.6
5.0
3.74.7
3.13.0
22.4
H2020 FUNDS ATTRACTED TO CATALONIA SHOW THE COMPETITIVINESS AND EXCELLENCE OF INSTITUTIONS, COMPANIES AND RESEARCHERS
Source: AGAUR from Eurostat 2013 / CORDA 2015
CATALONIA HAS ATTRACTED 73% MORE FUNDS FROM THE H2020 THAN THE TWO FIRST YEARS OF THE FP7. The two first years of H2020, Catalonia received 226.8 M€. Compared to other countries from the European Research Area (ERA) and with similar population, Catalonia overcomes Israel and Switzerland in absolute figures
DENMARK
FINLAND
AUSTRIA
CATALONIA
ISRAEL
SWITZERLAND 14
20
31
37
41
30
Country Inhabitants (in M) M€
Funding received per population
(ratio)
DENMARKFINLANDAUSTRIACATALONIAISRAELSWITZERLAND
5.6035.4278.4897.5477.7978.037
230.33119.79265.73226.77154.91108.67
413731302014
A WIDE RANGE OF CUTTING-EDGE FACILITIES THAT SUPPORT THE R&D SYSTEM
CENTER FOR GENOMIC REGULATION (CRG)
BARCELONA SUPERCOMPUTING CENTER (BSC - CNS)
ALBA SYNCHROTRON-CELLS
BARCELONA BIOMEDICAL RESEARCH PARK (PRBB)
BARCELONA SCIENCE PARK (PCB)
AND BRING TOGETHERTHE PLAYERS OF THEVALUE CHAIN:UNIVERSITIES, RESEARCHCENTERS AND COMPANIES
MORE THAN 100 PLATFORMS 2 LARGE INFRASTRUCTURES OF RESEARCH
13 SCIENCE AND TECHNOLOGY PARKS
5,499RESEARCHERS
8,716EMPLOYEES
780RESEARCH GROUPSWORKING ON LIFE
SCIENCES
41 RESEARCH CENTERS
NEW INITIATIVES AND GROUPINGS 2015: Barcelona Institute of Science and TechnologyBIST
+ +
CATALONIA,THE FOREMOST REGIONIN SPAIN IN TERMS OF
CLINICAL RESEARCH(2004-2011)
11 OUT OF THE
TOP20 BEST HOSPITALS IN SPAIN ARE LOCATED
IN CATALONIA
1ST
POSITION PERFORMING CLINICAL
TRIALS (27.3 %)
15 UNIVERSITY HOSPITALS AND9 HOSPITAL RESEARCH INSTITUTES
Source: Farmaindustria, IASIST (2015)
A HOT SPOT FOR BUSINESS AND INNOVATION7% GDP OF CATALONIA
Biotechnology- Therapeutics and diagnostics
Supplier & Engineering Investment entities
Professional Services and Consulting
Biotechnology - Other Pharma
Biotechnology - R&D services Medical Technology
734companies
6% 30%
13%
11%
28%
19%
13%
6%4%
Biotech
Pharma
Medtech
Others
TURNOVER (M€) COMPANIES
9,9892,910
14,2786,852
11,2443,092
6,6221,514
14,369M€ 42,133(4,000 in R&D)
WORKERS
Source: Biocat Directory
WHEN COMPARING NUMBER OF COMPANIES IN EUROPE, CATALONIA IS WITHIN THE TOP 5 LEADING COUNTRIESDESPITE BEING AMONG THE 5 SMALLEST COUNTRIES, CATALONIA STANDS IN THE TOP 5 IN NUMBER OF COMPANIES IN ALL SECTORSPer million inhabitants:- Biotech companies: Catalonia stands in 4th position after Sweden, Switzerland and Israel- Medtech companies: Catalonia stands in 4th position after Israel, Sweden and Switzerland- Pharma companies: Catalonia stands in 2nd
position, after Belgium
Million Inhabitants
2016
Biotech companies
Biotech Therapeutics companies
Medtech R&D
companies
Pharma companiesPer capita Per capita Per capita Per capita
AUSTRIA 8.713 94 10.79 40 4.59 52 5.97 15 1.72
BELGIUM 11.338 265 23.37 50 4.41 135 11.91 74 6.53
DENMARK 5.721 137 23.95 58 10.14 71 12.41 10 1.75
FINLAND 5.499 82 14.91 14 2.55 37 6.73 10 1.82
FRANCE 64.574 720 11.15 138 2.14 160 2.48 94 1.46
GERMANY 81.762 1,042 12.74 159 1.94 572 7.00 103 1.26
IRELAND 4.668 65 13.92 18 3.86 39 8.35 11 2.36
ISRAEL 8.377 334 39.87 154 18.38 545 65.06 36 4.30
ITALY 60.617 518 8.55 59 0.97 104 1.72 87 1.44
NETHERLANDS 17.008 409 24.05 86 5.06 117 6.88 40 2.35
NORWAY 5.240 120 22.90 27 5.15 32 6.11 8 1.53
SWEDEN 9.824 408 41.53 115 11.71 301 30.64 41 4.17
SWITZERLAND 8.362 346 41.38 104 12.44 230 27.51 47 5.62
UNITED KINGDOM 65.593 979 14.93 246 3.75 275 4.19 110 1.68
CATALONIA 7.516 221 29.40 45 5.99 94 12.51 46 6.12
Source: Site Selection for Life Sciences Companies in Europe 2015. KPMG & Venture Valuation
A CLUSTER IN EXPANSIONBETWEEN 2013-2015, ON AVERAGE, 3 NEW COMPANIES WERE FOUNDED PER MONTH (THAT IS 1 NEW VENTURE BORN IN HEALTHCARE EVERY 10 DAYS)
Source: Biotechegate. Biocat Directory, March 2016. The rest of the slides are based on company figures published at Biocat Report 2015 (September 2015)
+100 NEW ESTABLISHED COMPANIES FROM 2013 TO 2015
94 SPIN-OFF EMERGED FROM UNIVERSITIES,RESEARCH INSTITUTESAND HOSPITALS (ACTIVE AT 2015) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
825
623
828
324
225
338 3
35
141
40
37
31
3
New companies Inactive
COMPANIES ATTRACTED MORE THAN 100 M€ IN INVESTMENTS (2013-2015)
Source: BiotechGate. Biocat Directory: Last updated March 2016.
Capital raised by companies legally established at the BioRegion (thus it does not include Palobiopharma nor Sanifit)MAB: Spanish sub-market for smaller, growing companies
Direct investmentMAB
Projected December 2015 and March 2016
2009 201120102008
13.5610.60 10.50
10.61 11.00
29.50
10.6818
2.4455.16
3.62
3.44.31 4.3
2012 2013 2014 2015 2016
60
50
40
30
20
10
0
(in
M€)
87% OF BIOREGION COMPANIES ARE SMEsBIG COMPANIES ARE MAINLY MULTINATIONAL PHARMAs
Source: Biocat Directory / SABI
Over the past two years (2013-2015) the number of medium-sized companies has doubled and accounts for 22% of all companies, which is a sign of progressive consolidation in the sector
Medium-sized <250 ≤€50M ≤€43M
Small <50 ≤€10M ≤€10M
Micro <10 ≤€2M ≤€2M
Companycategory
Employees Balancesheet total
Turnover
Large companiesMedium-sized companies
Small companiesMicro-companies
40%
26%
22%
12%
734companies
58% OF COMPANIES ARE TRADING THEIR PRODUCTS IN INTERNATIONAL MARKETS
Source: Biocat Internationalization Survey 2015
THE MAIN MARKET FOR CATALAN COMPANIES IS SPAIN
Europe is the main destination for exports and international sales (mainly Germany, Italy and France) along with the United States
Collaborations Future entrySales
United States
Germany
United Kingdom
Spain
Italy
France
Mexico
Brazil
China
Japan
Colombia
Canada
India
Netherlands
Australia
South Korea
Israel
Argentina
Belgium
Sweden
19% 19% 26%
21% 16% 13%
13% 11% 14%
23% 11% 1%
18% 10% 7%
16% 7% 12%
14% 2% 2%
7% 1% 9%
7% 2% 6%
5% 3% 4%
4% 1% 6%
2% 6% 3%
2% 4% 3%
3% 3% 2%
3% 1% 4%
2% 2% 3%
2% 1% 4%
2% 2% 2%
1% 2% 2%
1% 2% 1%
BIOTECH: ACTIVITY OF COMPANIES
Source: Biocat Directory (December 2014)
THERAPIES & DIAGNOSTICS
R&D SERVICES
BIOTECH-OTHER*
ACTIVITIES COMPANIES
45
84
92
*Each company may be included into more than one category
2013 2015
0 10%5% 20%15% 30%25% 40%35% 45%
Environmental
AgBio
Industrial Biotechnology
Nutraceuticals
Cosmetics
Food
Veterinary
Others
BIOTECH & PHARMA: ACTIVITY OF COMPANIES(WORKING IN THERAPEUTIC AREAS)
Source: Biocat Directory
Each company can be included in more than one category
Generics 20%
18%
15%
10%
10%
9%
9%
8%
5,5%
3%
2%
2%
1%
1%
59%
Small molecules
Anti-infectives
Molecular diagnostics
Vaccines
Drug delivery
Antibodies
Peptides
Proteins
Gene therapy
Biosimilars
Cell therapy
Nucleic acid drugs
Stem cells
Others
0 20% 40% 60%
BIOTECH & PHARMA: ACTIVITY OF COMPANIES(OFFERING SERVICES R&D)
Source: Biocat Directory
CRO
Analytical services
Diagnostic services
CMO
Diagnostic instrumentation
Synthesis services
Genomics
Screening
Bioinformatics
Proteomics
Drug delivery
Cell culture
Biochips
Fill & finish
0 10% 20% 30% 40%
36%
25.5%
15%
14%
13%
12%
11%
7.5%
4%
3%
3%
3%
3%
0.5%
Others 29.5%
Each company can be included in more than one category
BIOTECH & PHARMA: MAIN THERAPEUTIC AREAS
Source: Biocat Directory
Neoplasms / cancer / oncology
Skin and subcutaneous tissue
Infectious and parasitic diseases
Diseases of the nervous system
Respiratory
Musculoskeletal system and connective tissue
Genitourinary system
Cardiovascular
Endocrine, nutritional and metabolic diseases
Diseases of the blood and blood-forming organs; immune disorders
Digestive system
Mental and behavioural disorders
Diseases of the eye
Pregnancy, childbirth and the puerperium
Diseases of the ear
Injury, poisoning and certain other consequences of external causes
External causes of morbidity and mortality
Congenital malformations, deformations and chromosomal abnormalities
Conditions originating in the perinatal period
0 10% 20% 30% 40%
37%
31%
27.5%
27.5%
22%
20%
20%
20%
19%
16.5%
15%
12%
10%
5%
4%
3%
1.5%
1.5%
1.5%
1.5%
Each company can be included in more than one category
MEDTECH: ACTIVITY OF COMPANIES (WORKING IN R&D, PRODUCTION AND MARKETING OF SYSTEMS AND DEVICES FOR MEDICAL APPLICATIONS IN HUMANS AND ANIMALS)
Source: Biocat Directory
Reusable instruments
Dental devices
Electro mechanical medical devices
Single use devices
Non-active implantable devices
Anesthetic and respiratory devices
Imaging
Diagnostic devices
Ophthalmic and optical devices
Technical aids for disabled persons
Diagnostic and therapeutic radiation devices
Biomaterials
Wound Care
Delivery devices
Hospital Hardware
Coatings
Regenerative Medicine
Others
0 10% 20% 30% 40%
COMPANIES WORKING IN MEDTECH:
R&D, PRODUCTION& MKT OFMEDICAL DEVICES
SOFTWARE, ELECTRONICS, INSTRUMENTATION OR DISTRIBUTION
94
106
200COMPANIES
19.5%
18%
17.5%
15%
12.5%
9.5%
9%
9%
9%
5%
4.5%
4.5%
2%
2%
2%
1%
1%
37%
Each company can be included in more than one category
WORLDWIDE INDUSTRY LEADERS CHOOSE THE BIOREGION AS THE BEST PLACE TO INVEST AND DO BUSINESSBIG MULTINATIONALS AND LOCAL BIG PLAYERS ESTABLISHED IN THE BIOREGIONBIOTECH & PHARMA MEDTECH
ACCELERATING PROGRAMS IN HEALTHCARE AT THE BIOREGIONEMPOWERING START-UPS AND ENTREPRENEURS TO SCALE UP THEIR BUSINESSES
PROGRAM / ACCELERATORCAIXAIMPULSE
d·HEALTH BARCELONA
HEALTH-U
SPIRE BIOVENTURES
WHAT IF! BARCELONA
GRANTS 4 APP
TECH4HEALTH
BSTARTUP
INCUBIO
INSPIRIT LABS
KAUTIC40
EMPENTA
IQSTECHFACTORY
STARTUPBOOTCAMP
STARTUP NEXT1
WAYRA
LIFE SCIENCES
LIFE SCIENCES
LIFE SCIENCES
LIFE SCIENCES
LIFE SCIENCES
DIGITAL HEALTH
DIGITAL HEALTH
IT
IT
IT
IT
ANY SECTOR
ANY SECTOR
ANY SECTOR
ANY SECTOR
ANY SECTOR
6 MONTHS
9 MONTHS
6 MONTHS
N/A
8 MONTHS
6 MONTHS
10 MONTHS
6 MONTHS
12 MONTHS
N/A
9 MONTHS
5 MONTHS
N/A
3 MONTHS
6 WEEKS
12 MONTHS
15 PROJECTS
3-4 PROJECTS
6 START-UPS
N/A
10 PROJECTS
4 START-UPS
15 START-UPS
10 START-UPS
7 START-UPS
1-2 PROJECTS
10 PROJECTS
15 PROJECTS
N/A
10 START-UPS
10 PROJECTS
10 PROJECTS
LA CAIXA
BIOCAT
SANOFI
SPIRE
INNOVATION FORUM
BAYER
HOSPITAL SANT JOAN DE DÉU, ESTEVE, CAIXA CAPITAL RISC, NAE, SHIP2B, DKV
BANC DE SABADELL
INCUBIO
INSPIRIT
ORBITAL 40
GENERALITAT DE CATALUNYA, ESADECREÁPOLIS
IQS
STARTUPBOOTCAMP
TECHSTARS
TELEFÒNICA
INDUSTRY DURATION COHORTSPROMOTERS
d·HEALTH BARCELONA
1 Last Startup Next Barcelona edition in April 2016
OUR LEADING TALENT
Valenti Fuster, cardiologistDirector of Mount Sinai Heart (New York). Editor-in-Chief of the Journal of the American College of Cardiology (JACC), past President of the American Heart Association
Josep Baselga, oncologistPhysician-in-Chief at Memorial Sloan Kettering Cancer Center (New York)
Josep M. Gatell, infectious diseasesHead of the Infectious Diseases and AIDS Units of the Hospital Clinic of Barcelona
Joan Massagué, oncologistDirector of the Sloan-Kettering Institute (New York). Internationally recognized leader in the study of cancer metastasis and cell behavior
Manel Esteller, oncologistDirector of the Cancer Epigenetics and Biology Program of the Bellvitge Institute for Biomedical Research (IDIBELL, Barcelona)
SUCCESS STORIES
CATALAN FIRM ORYZON
TO RECEIVE 21 M$ FROM
ROCHE TO DEVELOP
EPIGENETICS DRUGS
SUCCESS STORIESTHE COMPANY, SPECIALIZED IN DRUG DEVELOPMENT FOR RARE OR MINORITY DISEASES, GETS MOST SIGNIFICANT FUNDING IN BIOTECH SECTOR IN CATALONIA
MINORYX THERAPEUTICSCOMPLETES SERIES A FUNDINGOF 19.4 M€ (21.7 M$)
SUCCESS STORIES
REIG JOFRE AND NATRACEUTICAL AGREE TO
MERGER, CREATING FIFTH LARGEST PUBLICLY
TRADED PHARMACEUTICAL COMPANY
SUCCESS STORIES
AELIX THERAPEUTICS FINISHES SERIES A THERAPEUTIC HIV
VACCINE FUNDS
SUCCESS STORIES
STAT-DIAGNOSTICA
SECURES 22.1 M$ IN
SERIES B FINANCING
STAT-DIAGNOSTICA ANNOUNCES 25 M€IN SERIES C FINANCING
SUCCESS STORIES
MEDTEP CLOSES A 2 M$ INVESTMENT
AND MOVES TO SAN FRANCISCO
SUCCESS STORIES
GALGO MEDICAL RAISES 1 M€ IN FUNDING
More information about the BioRegion of Catalonia at:Biocat Report 2015
http://informe.biocat.cat/en
Follow us:
More information about the BioRegion of Catalonia at:Biocat Report 2015
http://informe.biocat.cat/en
Silver sponsors: